Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Oramed Pharm ( (ORMP) ) is now available.
On August 19, 2025, Oramed Pharmaceuticals Inc. held its Annual Meeting of Stockholders, where several key proposals were approved. Notably, the stockholders approved an amendment to the company’s 2019 Stock Incentive Plan, increasing the authorized shares for issuance by 2,000,000 to a total of 9,500,000 shares. This amendment, previously approved by the Board of Directors, allows officers and directors to receive awards under the plan. Additionally, the stockholders re-elected the company’s directors and ratified the appointment of Kesselman & Kesselman as the independent registered public accounting firm for the 2025 fiscal year.
Spark’s Take on ORMP Stock
According to Spark, TipRanks’ AI Analyst, ORMP is a Neutral.
Oramed Pharm’s overall score is driven by a strong balance sheet but hindered by poor income and cash flow performance. Technical indicators are neutral, and the valuation is typical for the industry. The absence of earnings call data and significant corporate events leaves fundamental concerns unaddressed.
To see Spark’s full report on ORMP stock, click here.
More about Oramed Pharm
Oramed Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development of oral drug delivery systems. The company is primarily known for its innovative oral insulin capsule, targeting diabetes treatment.
Average Trading Volume: 75,268
Technical Sentiment Signal: Strong Sell
Current Market Cap: $84.47M
For an in-depth examination of ORMP stock, go to TipRanks’ Overview page.